By Adriano Marchese

Regeneron Pharmaceuticals signed a new manufacturing-and-supply agreement with Fujifilm Diosynth Biotechnologies to double its large-scale manufacturing in the U.S.

Regeneron's new investment with Fujifilm, whose total value is estimated to exceed $3 billion, will expand the Tarrytown, N.Y., biotechnology company's manufacturing capabilities at Fujifilm's Holly Springs, N.C., campus, nearly doubling its large-scale capacity in the U.S.

This expansion will increase the production of bulk drug substances and Regeneron's commercial biologic medicines, the company said Tuesday.

Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm, which develops manufacturing for biologics, vaccines and advanced therapies, will provide Regeneron with access to its new state-of-the-art biopharmaceutical facility over a 10-year period.

The investment comes at the same time as Regeneron's initiatives in New York State, including a roughly $3.6 billion expansion of its Tarrytown campus that will bolster research, preclinical manufacturing and support facilities.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

April 22, 2025 06:54 ET (10:54 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.